These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 2139248)

  • 1. The effect of the one-chain to two-chain conversion in tissue plasminogen activator: characterization of mutations at position 275.
    Higgins DL; Lamb MC; Young SL; Powers DB; Anderson S
    Thromb Res; 1990 Feb; 57(4):527-39. PubMed ID: 2139248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis.
    Tate KM; Higgins DL; Holmes WE; Winkler ME; Heyneker HL; Vehar GA
    Biochemistry; 1987 Jan; 26(2):338-43. PubMed ID: 3103680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A region of tissue plasminogen activator that affects plasminogen activation differentially with various fibrin(ogen)-related stimulators.
    Eastman D; Wurm FM; van Reis R; Higgins DL
    Biochemistry; 1992 Jan; 31(2):419-22. PubMed ID: 1731899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variants of tissue-type plasminogen activator which display substantially enhanced stimulation by fibrin.
    Tachias K; Madison EL
    J Biol Chem; 1995 Aug; 270(31):18319-22. PubMed ID: 7629153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
    Nelles L; Lijnen HR; Collen D; Holmes WE
    J Biol Chem; 1987 Aug; 262(22):10855-62. PubMed ID: 2956260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator.
    Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
    J Biol Chem; 1988 Dec; 263(35):19083-91. PubMed ID: 3143723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical characterization of single-chain chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody and single-chain urokinase.
    Holvoet P; Laroche Y; Lijnen HR; Van Hoef B; Brouwers E; De Cock F; Lauwereys M; Gansemans Y; Collen D
    Eur J Biochem; 1992 Dec; 210(3):945-52. PubMed ID: 1483477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intact fibrin and partially plasmin-degraded fibrin on kinetic properties of one-chain tissue-type plasminogen activator.
    Fischer BE; Will H
    Biochim Biophys Acta; 1990 Oct; 1041(1):48-54. PubMed ID: 2145980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators.
    Urano S; Metzger AR; Castellino FJ
    Proc Natl Acad Sci U S A; 1989 Apr; 86(8):2568-71. PubMed ID: 2523073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The single-chain form of tissue-type plasminogen activator has catalytic activity: studies with a mutant enzyme that lacks the cleavage site.
    Boose JA; Kuismanen E; Gerard R; Sambrook J; Gething MJ
    Biochemistry; 1989 Jan; 28(2):635-43. PubMed ID: 2496749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical properties of recombinant single-chain urokinase-type plasminogen activator mutants with deletion of Asn2 through Phe157 and/or substitution of Cys279 with Ala.
    Lijnen HR; Li XK; Nelles L; Hu MH; Collen D
    Eur J Biochem; 1992 Apr; 205(2):701-9. PubMed ID: 1533368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variants of tissue-type plasminogen activator with substantially enhanced response and selectivity toward fibrin co-factors.
    Strandberg L; Madison EL
    J Biol Chem; 1995 Oct; 270(40):23444-9. PubMed ID: 7559505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.
    Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
    Eur J Biochem; 1988 Nov; 177(3):575-82. PubMed ID: 2973984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
    Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
    Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.
    Li XK; Lijnen HR; Nelles L; Hu MH; Collen D
    Biochim Biophys Acta; 1992 Sep; 1159(1):37-43. PubMed ID: 1390910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a modified human tissue plasminogen activator comprising a kringle-2 and a protease domain.
    Burck PJ; Berg DH; Warrick MW; Berg DT; Walls JD; Jaskunas SR; Crisel RM; Weigel B; Vlahos CJ; McClure DB
    J Biol Chem; 1990 Mar; 265(9):5170-7. PubMed ID: 2108167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The position of the structurally autonomous kringle 2 domain influences the functional features of tissue-type plasminogen activator.
    Bakker AH; Rehberg EF; Marotti KR; Verheijen JH
    Protein Eng; 1995 Mar; 8(3):293-300. PubMed ID: 7479691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA)--studies with active site mutagenized plasminogen and plasmin resistant t-PA.
    Lijnen HR; Van Hoef B; De Cock F; Collen D
    Thromb Haemost; 1990 Aug; 64(1):61-8. PubMed ID: 2148848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Artificial exon shuffling between tissue-type plasminogen activator (t-PA) and urokinase (u-PA): a comparative study on the fibrinolytic properties of t-PA/u-PA hybrid proteins.
    de Vries C; Veerman H; Blasi F; Pannekoek H
    Biochemistry; 1988 Apr; 27(7):2565-72. PubMed ID: 3132969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.